Saikiran K. Sedimbi

机构：Karolinska Institutet, Moderna Therapeutics (United States) · ORCID：0000-0001-5243-8395

发表论文 90 篇 · 总被引 1113 次 · h-index 15

代表论文

• MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia (2023 · Scientific Reports · 被引 12)
• Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2023 · Nature Communications · 被引 4)
• AID and TET2 cooperate to demethylate Irf4 for plasma cell fate in germinal center B cells (2026 · The Journal of Experimental Medicine · 被引 2)
• Functional mRNA delivery to hematopoietic stem and progenitor cells in vivo (2022 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 2)
• Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma. (2026 · Journal of Clinical Oncology)
• Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies (2025)